Al-Masri Mahmoud, Al-Shobaki Tawfiq, Al-Najjar Hani, Iskanderian Rafal, Younis Enas, Abdallah Niveen, Tbakhi Abdelghani, Haddad Hussam, Al-Masri Mohammad, Obeid Zeinab, Jarrar Awad
Department of Surgery, King Hussein Cancer Center, Amman, Jordan.
Department of Internal Medicine, Endocrine, King Hussein Cancer Center, Amman, Jordan.
Endocr Connect. 2021 Nov 25;10(12):1531-1537. doi: 10.1530/EC-21-0410.
This study focuses on the oncologic influence of BRAF V600E mutations in a cohort of Middle Eastern papillary thyroid carcinoma (PTC) patients treated at a single centre. We tested the association of BRAF V600E mutation with papillary thyroid carcinoma at King Hussein Cancer Center.
Patients with histologically confirmed PTC who underwent surgical treatment between 2006 and 2015 were included in this study. Oncological outcomes, both short- and long-termed, were collected.
A total of 128 patients (68% females) were included in this study with a mean age of 38 years (±13.8). The median follow-up period was 50 months. The BRAF V600E mutation was found in 71% of patients. The tumour size for patients with a negative BRAF V600E mutation was significantly larger in comparison to patients who tested positive for the mutation (3.47 cm vs 2.31 cm, respectively, P = 0.009). The two groups showed similar disease-free survival (DFS) rates; positive = 75% (median 43 months (0-168)) compared to 78% for the negative BRAF V600E mutation (median 38 months (3-142)) (P = 0.162, HR = 0.731) Furthermore, both groups showed similar overall survival rates, positive = 94.5% (median 56 months (0-228)) compared to 94.6% for the negative BRAF V600E mutation (median 43 months (3-157)) (P = 0.941, HR = 0.940).
BRAF V600E mutation had no effect on loco-regional recurrence, distant metastasis, overall survival, or DFS. These findings may be attributed to geographic variations or reflect that BRAF V600E may only serve as an indicator of poor prognosis in high-risk group as such.
本研究聚焦于在单一中心接受治疗的中东乳头状甲状腺癌（PTC）患者队列中BRAF V600E突变的肿瘤学影响。我们在侯赛因国王癌症中心测试了BRAF V600E突变与乳头状甲状腺癌的关联。
本研究纳入了2006年至2015年间接受手术治疗且组织学确诊为PTC的患者。收集了短期和长期的肿瘤学结局。
本研究共纳入128例患者（68%为女性），平均年龄38岁（±13.8）。中位随访期为50个月。71%的患者检测到BRAF V600E突变。BRAF V600E突变阴性患者的肿瘤大小明显大于突变阳性患者（分别为3.47 cm和2.31 cm，P = 0.009）。两组的无病生存率（DFS）相似；BRAF V600E突变阳性组为75%（中位43个月（0 - 168）），BRAF V600E突变阴性组为78%（中位38个月（3 - 142））（P = 0.162，HR = 0.731）。此外，两组的总生存率相似，BRAF V600E突变阳性组为94.5%（中位56个月（0 - 228）），BRAF V600E突变阴性组为94.6%（中位43个月（3 - 157））（P = 0.941，HR = 0.940）。
BRAF V600E突变对局部区域复发、远处转移、总生存率或DFS无影响。这些发现可能归因于地域差异，或反映出BRAF V600E仅可能作为高危组预后不良的一个指标。
